Početna › Burkittov limfom
Kliničke studije za Burkittov limfom koje traže sudionike u SAD-u
63 studija za Burkittov limfom traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX21 studija
- Milwaukee, WI16 studija
- Philadelphia, PA16 studija
- New York City, NY14 studija
- Chicago, IL14 studija
- Cincinnati, OH12 studija
- Atlanta, GA12 studija
- Seattle, WA11 studija
- Boston, MA10 studija
- Durham, NC10 studija
- Kansas City, MO10 studija
- Los Angeles, CA10 studija
- Aurora, CO10 studija
- Minneapolis, MN9 studija
- Orange, CA9 studija
- Washington, DC9 studija
- Baldwin Park, CA9 studija
- Columbus, OH8 studija
- Buffalo, NY8 studija
- Portland, OR8 studija
- Baltimore, MD8 studija
- Ann Arbor, MI8 studija
- San Francisco, CA8 studija
- Nashville, TN8 studija
- Tampa, FL7 studija
- Clifton, NJ7 studija
- Providence, RI7 studija
- Dallas, TX7 studija
- Richmond, VA7 studija
- Jacksonville, FL7 studija
- Grand Rapids, MI7 studija
- Oklahoma City, OK7 studija
- Greenburgh, NY7 studija
- Cleveland, OH7 studija
- Salt Lake City, UT7 studija
- Birmingham, AL7 studija
- San Antonio, TX7 studija
- The Bronx, NY6 studija
- Mountain View, CA6 studija
- Cicero, IL6 studija
Po državama
- Alabama7 studija
- Arizona7 studija
- Arkansas5 studija
- Colorado13 studija
- Connecticut7 studija
- Delaware7 studija
- Distrikt Columbia5 studija
- Florida15 studija
- Georgia12 studija
- Havaji5 studija
- Idaho6 studija
- Illinois14 studija
- Indiana6 studija
- Iowa7 studija
- Kalifornija20 studija
- Kansas6 studija
- Kentucky5 studija
- Louisiana4 studija
- Maine4 studija
- Maryland11 studija
- Massachusetts10 studija
- Michigan10 studija
- Minnesota10 studija
- Mississippi4 studija
- Missouri8 studija
- Nebraska5 studija
- Nevada6 studija
- New Hampshire4 studija
- New Jersey8 studija
- New Mexico3 studija
- New York20 studija
- North Carolina13 studija
- North Dakota5 studija
- Ohio17 studija
- Oklahoma7 studija
- Oregon8 studija
- Pennsylvania18 studija
- Rhode Island7 studija
- South Carolina5 studija
- South Dakota5 studija
- Tennessee10 studija
- Texas24 studija
- Utah7 studija
- Vermont3 studija
- Virginia7 studija
- Washington11 studija
- West Virginia3 studija
- Wisconsin17 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
U tijeku regrutacijaFaza 2
366 Days – 46 Years · Oba spola · Ažurirano 2. lis 2026. · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
U tijeku regrutacijaFaza 3
Od 18 do 39 godina · Oba spola · Ažurirano 2. lis 2026. · NCT03150693Blinatumomab Consolidation in Real World
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
U tijeku regrutacijaFaza 1/2
Od 3 do 39 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
U tijeku regrutacijaFaza 1/2
Od 18 do 120 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
U tijeku regrutacijaFaza 2
365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
U tijeku regrutacijaFaza 3
Od 1 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
U tijeku regrutacijaFaza 1
Od 0 do 18 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
U tijeku regrutacijaFaza 1/2
31 Days – 30 Years · Oba spola · Ažurirano 14. ruj 2026. · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
U tijeku regrutacijaFaza 2
Od 1 do 30 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 25. kol 2026. · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
U tijeku regrutacijaFaza 2
Od 7 do 25 godina · Oba spola · Ažurirano 19. kol 2026. · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
U tijeku regrutacijaFaza 2
Od 15 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.